Ronay G, Jäger W, Weiss K, Feistel H, Wolf F, Tulusan A H, Lang N
University of Erlangen, Department of Obstetrics and Gynecology, FRG.
Br J Cancer Suppl. 1990 Jul;10:67-9.
Benign and malignant tissue samples of 19 ovarian cancer patients who received an intravenous infusion of radiolabelled F(ab')2 fragments of OC125 were examined for expression of CA125 and the cellular location of the injected antibodies. CA125 could be detected by immunohistochemistry in 47 of 71 biopsies containing cancer cells, but not in 258 biopsies with benign tissue. F(ab')2 fragments were found in 34 of these 47 biopsies. The diffuse intracytoplasmic staining pattern seemed to indicate that the injected antibodies had crossed the membranes of the cancer cells. Since the antibody could not be detected in benign tissues, further applications of OC125 for diagnostic and therapeutic purposes seems to be justified.
对19例接受放射性标记的OC125 F(ab')2片段静脉输注的卵巢癌患者的良性和恶性组织样本进行了CA125表达及注射抗体细胞定位检查。在71份含有癌细胞的活检样本中,47份可通过免疫组织化学检测到CA125,但在258份良性组织活检样本中未检测到。在这47份活检样本中的34份发现了F(ab')2片段。弥漫性胞质内染色模式似乎表明注射的抗体已穿过癌细胞膜。由于在良性组织中未检测到该抗体,因此OC125在诊断和治疗方面的进一步应用似乎是合理的。